Arvinas Past Earnings Performance
Past criteria checks 2/6
Arvinas has been growing earnings at an average annual rate of 13.5%, while the Pharmaceuticals industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 33% per year. Arvinas's return on equity is 1.7%, and it has net margins of 2.9%.
Key information
13.51%
Earnings growth rate
20.07%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 33.01% |
| Return on equity | 1.65% |
| Net Margin | 2.94% |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
Seeking Alpha • Aug 28
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Summary Arvinas receives a Buy rating upgrade, underpinned by Veppanu’s FDA approval and a robust PROTAC platform. Despite Veppanu’s approval for ESR1-mutated breast cancer, ARVN’s share price remains near cash value, reflecting market skepticism about future revenues. ARVN’s pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside. Upcoming catalysts in neurology and oncology could trigger significant revaluation if positive data emerges from any Phase 1 programs. Read the full article on Seeking Alpha
Narrative Update • Aug 09
ARVN: Veppanu Out Licensing And Early Pipeline Execution Will Drive Future Upside
Arvinas' fair value estimate has been revised from $24.00 to $21.00 as analysts balance recent price target tweaks, including cuts tied to slower expected revenue progress and a higher discount rate, with support from the Rigel VEPPANU partnership and ongoing confidence in the early pipeline that underpins a higher future P/E assumption. Analyst Commentary Recent Street research on Arvinas points to a mixed but constructive backdrop, with several bullish analysts highlighting the VEPPANU partnership with Rigel and progress in the early pipeline as key supports for the stock's current valuation framework.
Narrative Update • Jun 17
ARVN: Licensing Deal Cash Flows Will Test Bullish Stock Price Expectations
Analysts have nudged their average price targets on Arvinas higher, into a mid to high teens dollar range, citing the new Veppanu licensing agreement with Rigel, the upfront $85 million payment with potential milestones up to $320 million, and the view that Rigel's existing U.S. oncology presence could help address what had been a key commercial overhang. Analyst Commentary on Arvinas Stock Recent research notes around Arvinas tend to cluster around the implications of the Veppanu partnership with Rigel and how that filters into valuation, risk, and the outlook for the early pipeline.Narrative Update • Jun 02
ARVN: Veppanu Licensing And Early Pipeline Progress Will Drive Future Upside
Analysts have raised the price target on Arvinas to $24 from $21, citing the Veppanu licensing deal with Rigel, the combination of upfront and milestone payments, and updated assumptions around growth, margins, and future P/E as the key drivers of their revised view. Analyst Commentary Recent research updates on Arvinas point to a cluster of higher price targets tied directly to the Veppanu licensing deal and the latest quarterly updates.Analysis Article • May 16
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • May 12
Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Narrative Update • May 01
ARVN: Early Neurology Readouts And Cash Runway Will Drive Bullish Repricing
Analysts have nudged Arvinas' implied price target higher by a few dollars per share, reflecting updated models after recent Q4 results, early approval for Vepdeg, and a fuller view of the upcoming data cycle for programs like ARV-102 and other 2026 readouts. Analyst Commentary Recent Street research on Arvinas clusters around early approval for Vepdeg, the updated Q4 models, and a more detailed path for ARV-102 and other 2026 data events.Narrative Update • Apr 17
ARVN: Upcoming Neurology Data Readouts Will Challenge Current Share Price Assumptions
Narrative Update on Arvinas Analysts have lifted their average price targets on Arvinas by several dollars per share, into a mid-teens to around $20 range. This reflects updated models after recent quarterly results, a busy calendar of expected ARV-102 data readouts across neurological indications, and views on the company’s multiyear cash runway.Narrative Update • Apr 03
ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Bullish Reassessment
Analysts have modestly raised the Arvinas fair value estimate from $14.56 to $14.88, reflecting higher Street price targets after recent Q4 model updates, expanded program timelines, and detailed cash runway assessments across multiple firms. Analyst Commentary Recent Street research presents a mixed but generally constructive picture for Arvinas, with several firms adjusting price targets higher following the Q4 update and program milestones.Narrative Update • Mar 20
ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Future Upside
The analyst price target for Arvinas has moved from $18 to $21, with analysts pointing to updated models that reflect revised assumptions around revenue growth, profit margins, and future P/E as they factor in recent quarterly results and upcoming clinical data readouts. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with bullish analysts pointing to refreshed models following quarterly results and upcoming clinical data.Narrative Update • Mar 05
ARVN: 2026 Neurology Readouts And Cash Runway Will Balance Execution Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved higher by $1.75, with analysts tying their updated views to refreshed post earnings models, a higher fair value estimate of $14.56, and anticipated 2026 data readouts for ARV-102 and other pipeline programs. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with analysts revising their models after the latest quarterly report and company updates.Narrative Update • Feb 19
ARVN: New Leadership And Lymphoma Program Will Drive Future Upside
Analysts have maintained their $18.00 price target for Arvinas, with updated assumptions that reflect adjusted views on revenue growth, profit margins, and future P/E expectations. What's in the News Arvinas appointed Randy Teel, Ph.D., as Chief Executive Officer, effective February 12, 2026.Narrative Update • Feb 05
ARVN: Hematology Data And Preclinical Combination Results Will Balance Cash Burn Risks
Analysts have nudged their price target on Arvinas slightly higher to about $12.81 from $12.75, citing updated assumptions around discount rates, revenue contraction, profit margins, and future P/E expectations. What's in the News Arvinas shared preclinical data for ARV-393, an investigational PROTAC BCL6 degrader, in combination with glofitamab at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida (Key Developments).Analysis Article • Jan 27
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Narrative Update • Jan 22
ARVN: New Hematology And KRAS Data Will Balance Cash Burn Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved slightly higher from US$12.44 to US$12.75. Analysts attribute this adjustment to updated assumptions for fair value, discount rate, profit margin, and future P/E.Narrative Update • Jan 07
ARVN: Future Returns Will Balance Breast Cancer Setbacks And Cash Burn Risks
Analysts have nudged their price target for Arvinas slightly higher to about $12.44 from $12.31, while highlighting rising concerns that competitive progress in hormone receptor positive, HER2 negative metastatic breast cancer could leave vepdegestrant at risk of becoming less relevant and keep investor focus on cash burn. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated average price target of about $12.44 as an indication that some on the Street still see room for upside relative to the most cautious views, even as competitive pressure builds around vepdegestrant.Narrative Update • Dec 16
ARVN: Early Neuroscience Pipeline Will Drive Future Upside Despite Breast Cancer Reset
Analysts have sharply cut their price target on Arvinas to about $18 from over $60. The change reflects heightened competitive pressure on vepdegestrant, uncertainty around out-licensing timelines, and a reset of expectations toward the company’s earlier-stage oncology and neuroscience pipeline.Narrative Update • Dec 02
ARVN: Refocus On Neuroscience And Cost Discipline Will Balance Risks And Opportunities
Analysts have revised Arvinas' price target lower. Notable cuts include Goldman's reduction to $6 from $8, reflecting heightened uncertainty around vepdegestrant's outlook and increased competitive pressures in breast cancer therapies.Narrative Update • Nov 18
ARVN: Core Oncology And Neuroscience Focus Will Drive Share Recovery Ahead
Arvinas' analyst price target has been revised downward from approximately $17.44 to $12.31 per share. Analysts cite increased competitive risks for vepdegestrant along with heightened uncertainty surrounding the company's future commercial prospects.Narrative Update • Sep 25
Precision Therapies Will Meet Demand Despite Clinical And Regulatory Risks
Arvinas’ consensus price target was reduced to $17.44, reflecting increased commercialization uncertainty for vepdegestrant following the decision to seek a third-party partner, restructuring, and delays to peak sales estimates despite ongoing support for the early-stage pipeline. Analyst Commentary Recent decision by Arvinas and Pfizer to seek a third-party partner for vepdegestrant has introduced significant uncertainty around commercialization timing and strategy, prompting downside risk to valuation.Analysis Article • Sep 09
Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified
Arvinas, Inc. ( NASDAQ:ARVN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Analysis Article • Jun 01
We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • May 01
Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are no doubt pleased to see that the share price has bounced 37% in the last...
New Narrative • Mar 24
Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles
Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.Seeking Alpha • Mar 14
Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Summary Arvinas' Vepdegestrant failed to show significant improvement over fulvestrant in the VERITAC-2 trial in the ITT population, leading to a 52% stock drop. Arvinas' enterprise value plummeted to -$400M, with a high cash burn rate and no advanced pipeline candidates to offset losses. Despite a healthy cash balance, the ARVN's burn rate and lack of near-term catalysts make it an unattractive investment; reiterate sell rating. Read the full article on Seeking AlphaAnalysis Article • Mar 12
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders that were waiting for something to happen have been dealt a blow with a 56...Seeking Alpha • Dec 25
Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Summary Arvinas, Inc. is a clinical-stage biotech firm focusing on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. We believe Arvinas is a short due to weak clinical data for ARV-471, which may not demonstrate compelling efficacy, risking a valuation collapse. Vepdegestrant (ARV-471) shows limited efficacy, likely due to poor bioavailability, and may not outperform existing treatments like fulvestrant in upcoming trials. Given Arvinas' significant cash burn and reliance on ARV-471, we expect a 30-40% stock price decline if Phase 3 results disappoint. Read the full article on Seeking AlphaAnalysis Article • Dec 24
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Arvinas, Inc.'s ( NASDAQ:ARVN ) price-to-sales (or "P/S") ratio of 11.1x might make it look like a strong sell right...Seeking Alpha • Oct 16
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Summary Arvinas, Inc.'s lead candidate, ARV-471, shows promise in phase 3 trials, especially in ESR1 mutant patients, but has mixed results in wild-type ESR1 patients. Despite past poor performance, recent positive data and a strong cash balance make ARVN a cautiously optimistic investment ahead of upcoming phase 3 data. Financially, Arvinas has a market cap of $1.78bn and a cash balance of $1.23bn, providing a runway of 8–9 quarters. While ARVN has potential, past inconsistent data warrants a cautious approach before investing further, despite promising recent developments. Read the full article on Seeking AlphaAnalysis Article • Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
A week ago, Arvinas, Inc. ( NASDAQ:ARVN ) came out with a strong set of second-quarter numbers that could potentially...Seeking Alpha • Jul 12
Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Summary Arvinas utilizes PROTAC technology to develop protein degraders, with vepdegestrant as a lead drug candidate in Phase 3 studies. Vepdegestrat will read out data from a large, late-stage study in breast cancer patients this year - a major catalyst to look out for. Data shared to date has been somewhat unconvincing and from small subsets - to secure approval, the drug will need to meet an endpoint of progression-free survival. The drug is also being tested in a Phase 3 study alongside Pfizer's Ibrance - some early promising data is not a cast iron guarantee of success. I'm a little lukewarm on Vepdegestrat's prospects and am downgrading my former "buy" rating to hold. Read the full article on Seeking AlphaAnalysis Article • Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Arvinas makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 317 | 9 | 84 | 237 |
| 31 Mar 26 | 89 | -221 | 87 | 283 |
| 31 Dec 25 | 263 | -81 | 95 | 283 |
| 30 Sep 25 | 312 | -58 | 107 | 306 |
| 30 Jun 25 | 373 | -73 | 161 | 507 |
| 31 Mar 25 | 427 | -47 | 168 | 348 |
| 31 Dec 24 | 263 | -199 | 165 | 348 |
| 30 Sep 24 | 161 | -309 | 158 | 360 |
| 30 Jun 24 | 93 | -323 | 105 | 181 |
| 31 Mar 24 | 71 | -355 | 100 | 284 |
| 31 Dec 23 | 79 | -367 | 100 | 380 |
| 30 Sep 23 | 159 | -295 | 88 | 383 |
| 30 Jun 23 | 158 | -298 | 86 | 374 |
| 31 Mar 23 | 137 | -301 | 84 | 346 |
| 31 Dec 22 | 131 | -282 | 80 | 315 |
| 30 Sep 22 | 127 | -253 | 83 | 279 |
| 30 Jun 22 | 103 | -233 | 79 | 242 |
| 31 Mar 22 | 75 | -213 | 70 | 210 |
| 31 Dec 21 | 54 | -191 | 62 | 180 |
| 30 Sep 21 | 23 | -180 | 55 | 152 |
| 30 Jun 21 | 21 | -164 | 48 | 141 |
| 31 Mar 21 | 21 | -139 | 43 | 122 |
| 31 Dec 20 | 26 | -119 | 38 | 108 |
| 30 Sep 20 | 24 | -99 | 33 | 96 |
| 30 Jun 20 | 47 | -86 | 32 | 82 |
| 31 Mar 20 | 45 | -78 | 30 | 75 |
| 31 Dec 19 | 43 | -70 | 27 | 67 |
| 30 Sep 19 | 42 | -65 | 26 | 61 |
| 30 Jun 19 | 15 | -173 | 22 | 58 |
| 31 Mar 19 | 14 | -179 | 17 | 52 |
| 31 Dec 18 | 14 | -240 | 13 | 45 |
| 30 Sep 18 | 13 | -233 | 8 | 37 |
| 30 Jun 18 | 12 | -114 | 5 | 31 |
| 31 Mar 18 | 10 | -98 | 4 | 29 |
| 31 Dec 17 | 8 | -29 | 4 | 29 |
| 31 Dec 16 | 7 | -12 | 3 | 20 |
Quality Earnings: ARVN has a large one-off loss of $7.7M impacting its last 12 months of financial results to 30th June, 2026.
Growing Profit Margin: ARVN became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARVN has become profitable over the past 5 years, growing earnings by 13.5% per year.
Accelerating Growth: ARVN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ARVN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).
Return on Equity
High ROE: ARVN's Return on Equity (1.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 08:17 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arvinas, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Tazeen Ahmad | BofA Global Research |